Ann: Preliminary Final Report, page-7

A bit of info copied from the report:-
"Sales & Marketing and Brand Awareness During the year the Company instigated key sales and marketing appointments in its major markets of the US, UK, and Europe, and has implemented a focused approach to generating and pursuing near-term sales leads in Patient Diagnostics and Clinical Trials, as well as progressing the reimbursement status for its products and services in key jurisdictions. The Company attended and presented abstracts at conferences including the Annual International Liver Congress (22-26 June 2022) and the European Hematology Congress (9-12 June 2022). New clinical trial and commercial sales opportunities were identified during these conferences and are being advanced. New Revenue Opportunities Six new clinical trials and clinical trial extensions were secured during the year in Resonance Health’s two focus areas of iron-overload and fatty-liver disease. One of these is the first clinical trial service contract secured in the large new Chinese market. Resonance Health also secured a contract with a new pharmaceuticals customer to assist with their clinical study Protocol for a new phase 2A pharmaceutical clinical trial. The Company is investigating potential new growth avenues in its service provision offering to pharmaceutical companies involved in clinical trials, in its core disease focus areas. Strategic Alliances During the year Resonance Health entered into a Patient Access Agreement with Thalassaemia International Federation (TIF), a non-profit, non-governmental organisation founded in 1986 and representing national thalassaemia associations in Cyprus, Greece, UK, USA and Italy. Pursuant to the Agreement TIF is to deploy FerriSmart® to thalassaemia patients in low-and-middle-income nations. In the March quarter the Company entered into a new channel partner agreement with Carpl.ai in India. Resonance Health’s HepaFat-Scan® service is to be featured by Carpl.ai in a study comparing HepaFat-Scan® with another fat assessment method, at the RSNA conference in the USA, in Nov-Dec 2022. "

Nothing immediate but these things do give promise of some reasonable expansion in the now non-Covid period.